Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

17411results about "Microcapsules" patented technology

Combination therapy

PCT designated stage expiredWO2025072649A1Antineoplastic agentsLiposomal delivery
A method for treating, inhibiting, or ameliorating cancer, such as KRAS-mutant cancer, including administering a GST-p inhibitor and either a KRAS inhibitor or a chemotherapy drug in therapeutically effective amounts to a subject suffering from the cancer in need thereof.
Owner:NITTO DENKO CORP

Polyglycerol stabilizing agents, compositions, uses, and manufacturing methods thereof

PCT designated stage expiredWO2025056465A1SsRNA viruses positive-senseOrganic chemistry
The invention provides stabilizing agents, compositions, methods of manufacturing, and uses thereof. In one aspect, a lipid nanoparticle composition includes: (a) an ionizable lipid; (b) two or more lipids; and (c) a stabilizing agent of formula (I) or formula (II) and methods for preparing the stabilizing agents and the lipid nanoparticle are provided.
Owner:GLOBAL LIFE SCI SOLUTIONS CANADA ULC +1

Method for enhancing mRNA-LNP tissue targeting delivery

The invention discloses a method for enhancing mRNA-LNP tissue targeting delivery. The invention provides a method for enhancing tissue targeting delivery of nucleic acid lipid nanoparticles, which comprises the following steps: modifying the surfaces of the nucleic acid lipid nanoparticles with tissue targeting with antibodies to obtain the nucleic acid lipid nanoparticles with modified antibodies and tissue targeting, the tissue targeting delivery property of the nucleic acid lipid nanoparticles is enhanced. On the basis of novel lung targeting LNP, an antibody modification strategy (double targeting) is combined, more efficient, specific and safer lung targeting mRNA delivery is successfully achieved, and the strategy is suitable for any type of targeting LNP (charge-driven DOTAP LNP and structure-driven STAR LNP in the project).
Owner:PEKING UNIV +1

Rapidly metabolized lipid compound

The invention provides a rapidly metabolized lipid compound, and particularly relates to a compound as shown in formula (I), or pharmaceutically acceptable salt, isotope variant, tautomer or stereoisomer thereof. The invention also provides nanoparticle pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions thereof in delivery of nucleic acids. # imgabs0 #
Owner:BEIJING JITAI PHARM TECH CO LTD +1

Polyphosphoester stabilizing agents, compositions, uses, and manufacturing methods thereof

PCT designated stage expiredWO2025056467A1Organic active ingredientsGenetic material ingredients
The invention provides stabilizing agents, compositions, methods of manufacturing, and uses thereof. In one aspect, a lipid nanoparticle composition including: (a) an ionizable lipid; (b) two or more lipids; and (c) a stabilizing agent of formula (I) and a method for preparing the stabilizing agent and the lipid nanoparticle are provided.
Owner:GLOBAL LIFE SCI SOLUTIONS CANADA ULC +1

Polyvinylpyrrolidone stabilizing agents, compositions, uses, and manufacturing methods thereof

PCT designated stage expiredWO2025056466A1Organic chemistryPeptide/protein ingredients
The invention provides stabilizing agents, compositions, methods of manufacturing, and uses thereof. In one aspect, a lipid nanoparticle composition includes: (a) an ionizable lipid; (b) two or more lipids; and (c) a stabilizing agent of formula (I) and a method for preparing the stabilizing agent and the lipid nanoparticle are provided.
Owner:GLOBAL LIFE SCI SOLUTIONS CANADA ULC +1

Dialkyl imidazole bionic lipid compound as well as preparation method and application thereof

The invention relates to a dialkyl imidazole bionic lipid compound and a preparation method and application thereof.The structure of the dialkyl imidazole bionic lipid compound imitates natural phospholipid design, alkyl with no less than 10 carbon atoms is modified on the fourth site and the fifth site of imidazole, and primary amines with different alkyl chain lengths are modified on the second site; the dialkyl imidazole bionic lipid compound is mixed with a therapeutic drug and other auxiliary materials to prepare lipid nanoparticles loaded with the therapeutic drug, and the lipid nanoparticles can be used as a drug delivery system for preparation of brain-targeted drugs. The dialkyl imidazole bionic lipid has the function of dynamically regulating and controlling the blood-brain barrier, and can realize reversible opening of the blood-brain barrier; the formed drug-loaded lipid composition can pass through a blood brain barrier and well realize brain-targeted delivery of loaded therapeutic drugs; the drug-loaded lipid composition composed of the dialkyl imidazole bionic lipid belongs to a new generation of bionic nano-drug carriers, and provides a new strategy for realizing brain-targeted delivery of different types of drugs.
Owner:UNITED NAOMI (TIANJIN) TECHNOLOGY CO LTD

Probiotic microcapsule with function of improving intestinal microecology and key technology

The invention relates to the technical field of biological pharmacy, and discloses a probiotic microcapsule with a function of improving intestinal microecology, which comprises the following components in percentage by weight: lactobacillus rhamnosus: each gram of formula contains 1010 CFU of lactobacillus rhamnosus; lactobacillus acidophilus: each gram of the formula contains 109 CFU; clostridium butyricum: each gram of the formula contains 108 CFU; 5%-8% of a nano sodium alginate-chitosan compound; 3%-5% of peptide nanoparticles; 2%-4% of a natural polymer intelligent response film; 3%-6% of arabinoxylan oligosaccharide; 4%-7% of resistant dextran; 2%-4% of lentinan; and 0.1%-0.3% of resveratrol. Through a double-layer or three-layer embedding technology of the nano sodium alginate-chitosan compound and the intelligent response polymer film, the tolerance of the probiotics in gastric acid and cholate environments is remarkably enhanced, and targeted release of the probiotics in small intestines and colon is ensured.
Owner:HENAN BUSINESS SCI RES INST

Ionizable lipid compound with three-dimensional space structure as well as preparation method and application of ionizable lipid compound

The invention relates to the technical field of nano delivery carriers, in particular to an ionizable lipid compound with a three-dimensional space structure and a preparation method and application thereof. The ionizable lipid compound provided by the invention comprises a three-dimensional space structure constructed by a polar head group, a connecting bond and a hydrophobic tail. Diversified ionizable lipid compounds with different three-dimensional space structures are constructed by changing various polar head groups, connecting bonds and hydrophobic tails contained in an ionizable lipid compound combinatorial library, and the ionizable lipid compounds have excellent mRNA (messenger ribonucleic acid) binding capacity. The invention also provides preparation and application of the ionizable lipid compound with the advantageous three-dimensional space structure. The novel ionizable lipid compound with an advantageous three-dimensional space structure has stronger binding capacity with mRNA, and lipid nanoparticles synthesized from the novel ionizable lipid compound have excellent physicochemical characteristics, high cell uptake rate, lysosome escape rate and cell and in-vivo transfection rate, and have the function of specifically targeting liver, spleen or lung.
Owner:THE NAT CENT FOR NANOSCI & TECH NCNST OF CHINA

Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof

The invention provides particles, compositions including the particles, and methods of making the particles using electrospray. In certain embodiments, the particles allow for high concentrations of a therapeutic or diagnostic agent to be delivered at low viscosity. Particles may also exhibit beneficial properties with respect to stability.
Owner:HALOZYME HYPERCON INC

Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof

The invention provides particles, compositions including the particles, and methods of making the particles using electrospray. In certain embodiments, the particles allow for high concentrations of a therapeutic or diagnostic agent to be delivered at low viscosity. Particles may also exhibit beneficial properties with respect to stability.
Owner:HALOZYME HYPERCON INC

Lipid nanoparticle compound for efficiently delivering nucleic acid to immune cells

The invention provides a lipid nanoparticle (LNP) compound for efficiently delivering nucleic acid to immune cells, and belongs to a biological medicine technology. According to the present invention, on the basis of the previously researched and developed ionizable cationic lipid 1-126, the Box-Behnken design is adopted to design 13 LNP formulas, and the microfluidic technology is adopted to complete the preparation of the LNP; by detecting the efficiency of LNP transfecting different immune cells and optimizing LNP components, the lipid nanoparticle compound for efficiently delivering mRNA in various immune cells is screened, the compound comprises 40% of cationic lipid 1-126, 16% of DSPC, 1.5% of DMG-PEG2000 and 42.5% of beta-sitosterol, and an efficient delivery system is provided for the fields of vaccine development and gene therapy.
Owner:ZHEJIANG UNIV OF TECH +1

Lipid nanoparticles comprising coding RNA molecules for use in gene editing and as vaccines and therapeutic agents

The present disclosure describes improved LNP-based RNA vaccines, nucleobase editing systems, and therapeutics for use in treating and / or immunization against disease. In particular, the disclosure describes improved LNPs, including novel and improved ionizable lipids for making LNPs, that enhance the targeted delivery of LNP-based RNA vaccines and therapeutics based on linear and / or circular mRNAs. The improved LNPs protect linear and / or circular mRNA payloads from degradation and clearance while achieving targeted systemic or local delivery for use as enhanced vaccines and / or therapeutic agents.
Owner:RENAGADE THERAPEUTICS MANAGEMENT INC

Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery

The present disclosure relates to ophthalmic compositions containing solid complexes of active pharmaceutical ingredient and cyclodextrin, to their method of preparation and their uses. The compositions can include an active agent drug / cyclodextrin complex substantially dissolved in an aqueous eye drop vehicle. The ophthalmic composition is generally in the form of a microsuspension including an active agent complex having a diameter of less than about 100 μm.
Owner:OCULIS OPERATIONS SARL

Lipid nanoparticle formulations and compositions

Disclosed are compositions of lipid nanoparticles (LNP) comprising an ionizable cationic lipid, a phospholipid, a sterol, and a PEG-lipid (non-functionalized and optionally functionalized). The functionalized PEG-lipid can be conjugated with a binding moiety to create a targeted LNP (tLNP). The disclosed tLNP preferentially deliver a nucleic acid molecule or other negatively charged payload to cells expressing a cell surface antigen recognized by the binding moiety of the tLNP, and are better tolerated, as compared to LNPs and tLNPs comprising ionizable cationic lipids found in marketed pharmaceuticals comprising LNPs.
Owner:CAPSTAN THERAPEUTICS INC

UTR (Untranslated Region) element H2202 P1-G as well as construction method and application thereof

The invention provides an UTR (Untranslated Region) element H2202 P1-G as well as a construction method and application thereof, and relates to the technical field of mRNA (messenger ribonucleic acid). According to the present invention, the ribosome load prediction and the secondary structure optimization are performed on the natural 5 'UTR of the HIV TAT 202 gene through the BaidleHelix platform, and the obtained HTAT 202 P1 sequence avoids the inhibitory hairpin structure so as to significantly improve the luciferase expression quantity compared to the natural UTR; an ncRNA sequence without a secondary structure is introduced on the basis of the HTAT 202 P1, translation inhibition of a 5 'cap region is further relieved, and the protein expression quantity of the constructed H2202 P1-G mutant (the DNA sequence of the H2202 P1-G is as shown in SEQ NO 1, and the RNA sequence is as shown in SEQ NO 2) is further improved.
Owner:INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI

Preparation method of active peptide and stem cell exosome mixed hair restorer

The invention provides a preparation method of a mixed pilatory of active peptide and stem cell exosome, and belongs to the technical field of pilatory preparation. The preparation method comprises the following steps: extracting the stem cell exosome; extracting an active extract; preparing an exosome entrapped active extract; preparing the liposome loaded active peptide; preparing the liposome loaded active peptide modified by the gallic acid modified chitosan; and preparing the mixed hair restorer. The prepared mixed hair restorer can provide a suitable growth environment for hair follicles and promote hair growth, the synergistic effect of the active peptide and the exosome can provide abundant signal molecules and enhance the stimulation effect on hair follicle cells, and the active peptide and the exosome can promote angiogenesis and increase the blood flow volume of scalp, so that the hair follicle can be effectively promoted. More nutrition and oxygen are provided for hair follicles, and the growth of hair is effectively promoted.
Owner:BEIJING BOSHIYUAN HAIR RES CENT

Lipids and compositions thereof

The present disclosure relates to cationic and / or ionizable lipids and nucleic acid-lipid particle compositions comprising the same. The present disclosure also relates to methods of using and delivering the described lipids and lipid-containing particles.
Owner:KERNAL BIOLOGICS INC

Application of ganoderma lucidum exosome in treatment of brain glioma, extraction method and composition

The invention relates to the technical field of biological products, and provides an application of a ganoderma lucidum exosome in treatment of brain glioma, an extraction method and a composition, and the application of the ganoderma lucidum exosome in any one or more of the following applications: a) preparing a product for promoting apoptosis of brain glioma cells; b) preparing a product for inhibiting brain glioma cell proliferation; c) preparing a product for inhibiting autophagy of brain glioma cells; and d) preparing a product for treating the brain glioma. It is verified through cell and animal experiments that the ganoderma lucidum exosome can effectively induce apoptosis of the brain glioma cells and inhibit autophagy of the brain glioma cells to induce death of the brain glioma cells, and acts on the brain glioma cells through an AKT / mTOR signal channel and inhibition of generation of autophagosome of the brain glioma cells.
Owner:LIAOCHENG PEOPLES HOSPITAL

Nano transdermal delivery system based on superoxide dismutase and preparation method thereof

The invention provides a nano transdermal delivery system based on superoxide dismutase, the nano transdermal delivery system is of a capsule composite structure of a small molecule active component-superoxide dismutase-polymer shell layer, the small molecule active component is loaded in superoxide dismutase, the surface of the superoxide dismutase is coated by the polymer shell layer, and the superoxide dismutase is loaded in the capsule composite structure. The diameter of the superoxide dismutase-based active ingredient transdermal delivery system is 20-100 nm, and the thickness of the polymer shell layer is 7.5-52.5 nm. In the delivery system, the polymer shell layer provides a protection effect for the superoxide dismutase and the micromolecular functional substances with the anti-oxidation effect, the capsule composite structure is in a nanogel form, and the nanogel not only promotes the penetration depth of the capsule, but also reduces the irritation effect of the capsule on the skin. The raw materials are biologically friendly, the preparation method is simple, the yield is high, and industrial large-scale production can be realized.
Owner:SHANGHAI JIAOTONG UNIV +1

Lipids and compositions thereof

Provided herein are lipids having the Formula I or Formula Ia:and pharmaceutically acceptable salts thereof, wherein R′, R1, R2, R3, R4, R5, R6a, R6b, X1, X2, and n are as defined herein for Formula I and Formula Ia, respectively. Also provided herein are lipid nanoparticle (LNP) compositions comprising lipid having the Formula I or Ia and a capsid-free, non-viral vector (e.g., ceDNA). In one aspect of any of the aspects or embodiments herein, these LNPs can be used to deliver a capsid-free, non-viral DNA vector to a target site of interest (e.g., cell, tissue, organ, and the like).
Owner:GENERATION BIO CO

Formation of particles including agents

The invention provides methods for the preparation of particles including one or more agents, e.g., therapeutic or diagnostic agents. The particles can be formed by creating droplets of a first liquid, e.g., including an agent, and removing the first liquid, e.g., through its dispersal in a second liquid and / or evaporation, to solidify the droplets. Advantageously, the process of forming the particles does not significantly alter the structure or activity of the agents and may enhance the stability of the agents. For example, the particles may be stored for long periods of time without significant loss of activity, and in some embodiments, without the need for refrigeration. These particles may be used to generate stabilized pharmaceutical compositions for storage or other logistical purposes, pharmaceutical suspensions, pharmaceutical powder formulations (e.g., inhalable powders, injectable powders), creams or other topical pastes, nutraceuticals, or cosmetics.
Owner:HALOZYME HYPERCON INC

Particles consisting of an organic polymer core, a first inorganic oxide shell incorporating a magnetic material and a mesoporous second inorganic shell

A core-shell particle having an organic polymer core which is completely covered by a first inorganic oxide shell, wherein the first inorganic oxide shell has a silica (SiO2), an alumina (Al2O3), or a titania (TiO2); wherein the first inorganic oxide shell has a layer of a magnetic material which is disposed directly on the polymer core; further having a mesoporous second inorganic oxide shell, wherein the mesoporous second inorganic oxide shell covers the first inorganic oxide shell; wherein the mesoporous second inorganic oxide shell has silica (SiO2), alumina (Al2O3), or a titania (TiO2).
Owner:BUNDESREPUBLIK DEUTSCHLAND VERTRETEN DURCH DEN BUNDESMINISTER FUR WIRTSCHAFT UND ENERGIE DIESER VERTRETEN DURCH DEN PRASIDENTEN DER BUNDESANSTALT FUR MATERIALFORSCHUNG UND PRUFUNG (BAM)

Medical silver-containing porous polyurethane foam

The invention relates to a polyurethane foam technology in the technical field of medical dressings, in particular to medical silver-containing porous polyurethane foam. The composite material comprises a foam matrix, the foam matrix adopts gradient layering design and comprises a matrix inner layer, a matrix middle layer and a matrix outer layer, the aperture of each layer is sequentially increased, the porosity is gradually increased layer by layer, the matrix inner layer is provided with randomly dispersed inner-layer hollow silver-loaded fibers capable of slowly releasing silver ions for bacteriostasis, the matrix middle layer is fixedly provided with pH response microcapsules, and the pH response microcapsules are fixed on the matrix outer layer. In an alkaline environment, antibacterial peptides are released for synergic antibiosis, and silver-loaded fibers in the outer layer of the matrix outer layer are arranged in the radial direction to form a flow guide channel and release silver ions. Through gradient layered design, different sterilization structures are added, the temperature-sensitive hydrogel layer covering the surface of the outer layer of the base body is matched, sterilization and seepage are managed through environmental changes, and the advantages of being excellent in antibacterial performance, high in seepage management capacity, intelligent in adjustment and the like are achieved.
Owner:思利康医用材料(天长)有限公司

Cationic lipids for use in lipid nanoparticles

Compounds are provided having the following structure:or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein a, b, c, d, G1, G2, L1, L2, R1a, R1b, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6, R7, R8 and X are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, nanoparticles comprising the compounds and methods for their use and preparation are also provided.
Owner:ACUITAS THERAPEUTICS INC

Glucose response type insulin delivery system as well as preparation method and application thereof

The invention discloses a glucose response type insulin delivery system as well as a preparation method and application thereof, and belongs to the technical field of biological materials. The glucose response type insulin delivery system provided by the invention comprises a delivery carrier and a bioactive component encapsulated in the carrier, the delivery carrier is a metal polyphenol network formed by carrying out coordination reaction on epigallocatechin gallate and metal ions; the bioactive components comprise glucose oxidase, catalase and insulin. The glucose response type insulin delivery system provided by the invention can adjust the release of insulin according to the concentration of glucose in the surrounding environment, so that the blood glucose is maintained at a normal level.
Owner:ZHEJIANG UNIV +1